Detalhe da pesquisa
1.
Outcome of carfilzomib/pomalidomide-based regimens after daratumumab-based treatment in relapsed multiple myeloma: A Canadian Myeloma Research Group Database analysis.
Eur J Haematol
; 111(5): 815-823, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37574220
2.
Outcomes of daratumumab in the treatment of multiple myeloma: A retrospective cohort study from the Canadian Myeloma Research Group Database.
Br J Haematol
; 198(1): 93-102, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35383886
3.
Real-world outcomes with bortezomib-containing regimens and lenalidomide plus dexamethasone for the treatment of transplant-ineligible multiple myeloma: a multi-institutional report from the Canadian Myeloma Research Group database.
Br J Haematol
; 193(3): 532-541, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33559897
4.
Retrospective study of treatment patterns and outcomes post-lenalidomide for multiple myeloma in Canada.
Eur J Haematol
; 107(4): 416-427, 2021 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-34129703
5.
A descriptive cost-analysis of MYX.1/MCRN003, a phase 2 clinical trial evaluating high-dose weekly carfilzomib, cyclophosphamide, and dexamethasone in relapsed and refractory multiple myeloma.
Eur J Haematol
; 107(3): 333-342, 2021 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-34053112
6.
The impact of lenalidomide maintenance on second-line chemotherapy in transplant eligible patients with multiple myeloma.
Eur J Haematol
; 106(5): 673-681, 2021 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-33539037
7.
Weekly carfilzomib plus cyclophosphamide and dexamethasone in the treatment of relapsed/refractory multiple myeloma: Final results from the MCRN-003/MYX.1 single arm phase II trial.
Am J Hematol
; 96(5): 552-560, 2021 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33650179
8.
The survival impact of maintenance lenalidomide: an analysis of real-world data from the Canadian Myeloma Research Group national database.
Haematologica
; 106(6): 1733-1736, 2021 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33054120
9.
Belantamab mafodotin, pomalidomide and dexamethasone in refractory multiple myeloma: a phase 1/2 trial.
Nat Med
; 30(2): 543-551, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-38177852
10.
A Phase II, Open-Label Study of an Accelerated Infusion Rate of Daratumumab in Patients With Relapsed and Refractory Multiple Myeloma.
Clin Lymphoma Myeloma Leuk
; 23(7): 484-490, 2023 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37127473
11.
Real-world results of autologous stem cell transplantation in newly diagnosed multiple myeloma: a report from the Canadian Myeloma Research Group database.
Blood Cancer J
; 13(1): 137, 2023 09 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-37669949
12.
Redefining attrition in multiple myeloma (MM): a Canadian Myeloma Research Group (CMRG) analysis.
Blood Cancer J
; 13(1): 111, 2023 07 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-37474492
13.
Real-world data on lenalidomide dosing and outcomes in patients newly diagnosed with multiple myeloma: Results from the Canadian Myeloma Research Group Database.
Cancer Med
; 12(4): 4357-4362, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36161712
14.
Carfilzomib usage patterns and outcomes in patients with relapsed multiple myeloma: A multi-institutional report from the Canadian Myeloma Research Group (CMRG) Database.
EJHaem
; 3(4): 1252-1261, 2022 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-36467802
15.
Efficacy of Daratumumab-Containing Regimens Among Patients With Multiple Myeloma Progressing on Lenalidomide Maintenance: Retrospective Analysis.
Front Oncol
; 12: 826342, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35251992
16.
Sequential Use of Carfilzomib and Pomalidomide in Relapsed Multiple Myeloma: A Report from the Canadian Myeloma Research Group (CMRG) Database.
Curr Oncol
; 29(3): 1575-1582, 2022 03 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-35323332
17.
Survival and Outcomes of Newly Diagnosed Multiple Myeloma Patients Stratified by Transplant Status 2007-2018: Retrospective Analysis from the Canadian Myeloma Research Group Database.
Clin Lymphoma Myeloma Leuk
; 22(8): 608-617, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35379589
18.
A phase-1 trial of linsitinib (OSI-906) in combination with bortezomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma.
Leuk Lymphoma
; 62(7): 1721-1729, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-33509009
19.
Correction: Redefining attrition in multiple myeloma (MM): a Canadian Myeloma Research Group (CMRG) analysis.
Blood Cancer J
; 13(1): 129, 2023 Aug 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-37635183